Martyn Ronald Schaafsma

Author

Medisch Spectrum Twente

Also Known As

M R Schaafsma, M. R Schaafsma, M. R. Schaafsma, M.R. Schaafsma, Martyn R. Schaafsma, Martyn Ronald Schaafsma

Publications

520

Citations

H-Index

Concepts

All Affiliations

Medisch Spectrum Twente Amsterdam UMC Location Vrije Universiteit Amsterdam Isala Haga Hospital University Medical Center Groningen

About

Martyn Ronald Schaafsma is an author at Medisch Spectrum Twente specializing in hematology, medicine, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	223
2	Immunology	2	2	94
3	Health Sciences	1	1	129
4	Cell Biology	1	1	30
5	Cellular Therapies	1	1	30

Martyn Ronald Schaafsma

Publications

468

Citations

H-Index

Page 1

	Year	Citations
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years Jan J. Cornelissen, Jurjen Versluis, Jakob Passweg, Leukemia Hematological MalignancyPost-remission ApproachesMedicineAcute Myeloid LeukemiaHematology	2014	129
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial Christoph Scheid, P. Sonneveld, Ingo Schmidt‐Wolf, Haematologica	2013	126
Apoptosis and Secondary Necrosis of Lymphocytes in Culture I. Vermes, C Haanen, Dick J. Richel, Acta Haematologica Vitro ApoptosisApoptosisImmunologyPathologyCell Death	1997	64
Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study Kim Holtzer-Goor, Martyn Ronald Schaafsma, Peter Joosten, Quality of Life Research	2015	52
Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy Mels Hoogendoorn, Judith Olde Wolbers, W. M. Smit, Leukemia Hematological MalignancyCell TherapyTransplantationImmunologyHematology	2004	30
Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial Pieter Sonneveld, Christof Scheid, Bronno van der Holt, Blood	2013	24
Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM) Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman, Blood	2008	16
Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study Jeanette K. Doorduijn, Monique C. Minnema, Marie José Kersten, Blood	2015	15
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy Francesco d’Amore, Sirpa Leppä, María Gomes da Silva, Blood	2012	12

Page 1